Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Sedative Plasma Concentrations and Delirium Risk in Critical Illness.

Stollings JL, Thompson JL, Ferrell BA, Scheinin M, Wilkinson GR, Hughes CG, Shintani AK, Ely EW, Girard TD, Pandharipande PP, Patel MB.

Ann Pharmacother. 2018 Jun;52(6):513-521. doi: 10.1177/1060028017753480. Epub 2018 Jan 24.

2.

Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.

Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, Floyd M, Stein CM, Wilkinson GR.

J Infect Dis. 2009 Mar 15;199(6):872-80. doi: 10.1086/597125.

3.

Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein.

Kurnik D, Sofowora GG, Donahue JP, Nair UB, Wilkinson GR, Wood AJ, Muszkat M.

Anesthesiology. 2008 Dec;109(6):1092-9. doi: 10.1097/ALN.0b013e31818d8f28.

PMID:
19034106
4.

Clinical sedation scores as indicators of sedative and analgesic drug exposure in intensive care unit patients.

Masica AL, Girard TD, Wilkinson GR, Thomason JW, Truman Pun B, Nair UB, Light RW, Canonico AE, Dunn J, Pandharipande P, Shintani AK, Ely EW.

Am J Geriatr Pharmacother. 2007 Sep;5(3):218-31.

PMID:
17996661
5.

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.

Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW.

Pharmacogenet Genomics. 2006 Nov;16(11):837-45.

PMID:
17047492
6.

The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.

Kurnik D, Wood AJ, Wilkinson GR.

Clin Pharmacol Ther. 2006 Sep;80(3):228-34.

PMID:
16952489
7.

Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.

Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, Rousseau F, Ingram CD, Shaw A, Lederman MM, Kim RB; Adult AIDS Clinical Trials Group.

Clin Infect Dis. 2006 Sep 15;43(6):783-6. Epub 2006 Aug 15.

PMID:
16912957
8.

Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier.

Choo EF, Kurnik D, Muszkat M, Ohkubo T, Shay SD, Higginbotham JN, Glaeser H, Kim RB, Wood AJ, Wilkinson GR.

J Pharmacol Exp Ther. 2006 Jun;317(3):1012-8. Epub 2006 Mar 14.

PMID:
16537797
9.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H.

Pharmacogenet Genomics. 2006 Feb;16(2):101-10.

PMID:
16424822
10.

Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients.

Pandharipande P, Shintani A, Peterson J, Pun BT, Wilkinson GR, Dittus RS, Bernard GR, Ely EW.

Anesthesiology. 2006 Jan;104(1):21-6.

PMID:
16394685
11.

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.

Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP; Adult AIDS Clinical Trials Group Study.

Clin Infect Dis. 2006 Feb 1;42(3):401-7. Epub 2005 Dec 27.

PMID:
16392089
12.

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Jr, Donahue JP, Kim RB.

J Infect Dis. 2005 Dec 1;192(11):1931-42. Epub 2005 Nov 1.

PMID:
16267764
13.

Drug metabolism and variability among patients in drug response.

Wilkinson GR.

N Engl J Med. 2005 May 26;352(21):2211-21. Review. No abstract available.

PMID:
15917386
14.

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP.

AIDS. 2004 Dec 3;18(18):2391-400.

PMID:
15622315
15.

In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.

Masica AL, Mayo G, Wilkinson GR.

Clin Pharmacol Ther. 2004 Oct;76(4):341-9.

PMID:
15470333
16.

Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions.

Wilkinson GR.

Clin Pharmacol Ther. 2004 Aug;76(2):99-103. No abstract available.

PMID:
15289786
17.

CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.

Takahashi H, Wilkinson GR, Padrini R, Echizen H.

Clin Pharmacol Ther. 2004 May;75(5):376-80. Review. No abstract available.

PMID:
15116049
18.

Genetic variability in CYP3A5 and its possible consequences.

Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR.

Pharmacogenomics. 2004 Apr;5(3):243-72. Review.

PMID:
15102541
19.

5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.

Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K, Echizen H.

Blood. 2004 Apr 15;103(8):3055-7. Epub 2003 Dec 30.

PMID:
15070684
20.

MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study.

Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, Landay A, Connick E, Benson C, Wilkinson GR, Kessler H, Kim RB.

J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):295-8.

PMID:
14600574
21.

A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.

Haas DW, Wilkinson GR, Kuritzkes DR, Richman DD, Nicotera J, Mahon LF, Sutcliffe C, Siminski S, Andersen J, Coughlin K, Clayton EW, Haines J, Marshak A, Saag M, Lawrence J, Gustavson J, Anne Bennett J, Christensen R, Matula MA, Wood AJ; Adult AIDS Clinical Trials Group.

HIV Clin Trials. 2003 Sep-Oct;4(5):287-300.

PMID:
14583845
22.

Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.

Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR.

Pharmacogenetics. 2003 Oct;13(10):595-606.

PMID:
14515058
23.

Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.

Dalén P, Dahl ML, Roh HK, Tybring G, Eichelbaum M, Wilkinson GR, Bertilsson L.

Br J Clin Pharmacol. 2003 Jun;55(6):630-4.

24.

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.

Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H.

Clin Pharmacol Ther. 2003 Mar;73(3):253-63.

PMID:
12621390
25.

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.

Dresser GK, Schwarz UI, Wilkinson GR, Kim RB.

Clin Pharmacol Ther. 2003 Jan;73(1):41-50.

PMID:
12545142
26.

Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects.

Rogers JF, Nafziger AN, Kashuba AD, Streetman DS, Rocci ML Jr, Choo EF, Wilkinson GR, Bertino JS Jr.

J Clin Pharmacol. 2002 Oct;42(10):1079-82.

PMID:
12362920
27.

Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans.

Poland RA, Lin KM, Nuccio C, Wilkinson GR.

Clin Pharmacol Ther. 2002 Sep;72(3):288-93.

PMID:
12235449
28.

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.

Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, Kashuba AD, Kulawy RW, Beck DJ, Rocci ML Jr, Wilkinson GR, Greenblatt DJ, Bertino JS Jr.

J Clin Pharmacol. 2002 Apr;42(4):376-82.

PMID:
11936561
29.

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.

Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, Shen DD, Watkins PB, Wilkinson GR, Kharasch ED, Thummel KE.

Pharmacogenetics. 2001 Dec;11(9):781-91.

PMID:
11740342
30.

Identification of functionally variant MDR1 alleles among European Americans and African Americans.

Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR.

Clin Pharmacol Ther. 2001 Aug;70(2):189-99.

PMID:
11503014
31.

In vivo inhibition of human CYP1A2 activity by oltipraz.

Sofowora GG, Choo EF, Mayo G, Shyr Y, Wilkinson GR.

Cancer Chemother Pharmacol. 2001 Jun;47(6):505-10.

PMID:
11459203
32.

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.

Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI.

Mol Pharmacol. 2001 Aug;60(2):382-7.

PMID:
11455026
33.

CYP3A activity in European American and Japanese men using midazolam as an in vivo probe.

Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y, Kobayashi S, Thummel KE, Wilkinson GR.

Clin Pharmacol Ther. 2001 May;69(5):333-9.

PMID:
11372001
34.

Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma.

Haas DW, Clough LA, Johnson BW, Harris VL, Spearman P, Wilkinson GR, Fletcher CV, Fiscus S, Raffanti S, Donlon R, McKinsey J, Nicotera J, Schmidt D, Shoup RE, Kates RE, Lloyd RM Jr, Larder B.

AIDS Res Hum Retroviruses. 2000 Oct 10;16(15):1491-502.

PMID:
11054262
35.

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.

Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR.

Clin Pharmacol Ther. 2000 Jul;68(1):82-91.

PMID:
10945319
36.
37.

Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.

Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB.

Drug Metab Dispos. 2000 Jun;28(6):655-60.

PMID:
10820137
38.

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.

Dalén P, Dahl ML, Eichelbaum M, Bertilsson L, Wilkinson GR.

Pharmacogenetics. 1999 Dec;9(6):697-706.

PMID:
10634132
39.

Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.

Tennezé L, Verstuyft C, Becquemont L, Poirier JM, Wilkinson GR, Funck-Brentano C.

Clin Pharmacol Ther. 1999 Dec;66(6):582-8.

PMID:
10613613
40.
41.

Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity.

Kim RB, Leake B, Cvetkovic M, Roden MM, Nadeau J, Walubo A, Wilkinson GR.

J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9.

PMID:
10565843
42.

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.

Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, Wilkinson GR.

Clin Pharmacol Ther. 1999 Sep;66(3):224-31.

PMID:
10511057
43.

Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.

Xie HG, Kim RB, Stein CM, Wilkinson GR, Wood AJ.

Br J Clin Pharmacol. 1999 Sep;48(3):402-8. Erratum in: Br J Clin Pharmacol 2001 Sep;52(3):343.

44.

P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.

Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ.

Cancer Res. 1999 Aug 15;59(16):3944-8.

45.

OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.

Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB.

Drug Metab Dispos. 1999 Aug;27(8):866-71.

PMID:
10421612
46.

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA.

J Pharmacol Exp Ther. 1999 Aug;290(2):635-40.

PMID:
10411572
47.

Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone.

Marchand LL, Wilkinson GR, Wilkens LR.

Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):495-500.

48.

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR.

Pharm Res. 1999 Mar;16(3):408-14.

PMID:
10213372
49.

Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio.

Kinirons MT, Krivoruk Y, Wilkinson GR, Wood AJ.

Br J Clin Pharmacol. 1999 Feb;47(2):223-5. No abstract available.

50.

An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.

Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA.

Pharmacogenetics. 1998 Apr;8(2):129-35.

PMID:
10022751

Supplemental Content

Loading ...
Support Center